MiNK Therapeutics (NASDAQ:INKT) CEO Sells $73,265.28 in Stock

Key Points

• CEO Jennifer Buell sold 6,938 MiNK Therapeutics shares for approximately $73,265, reducing her stake by 8.55%. The sale was reportedly made to cover tax withholding obligations tied to vested equity awards.
• MiNK shares traded at $10.26, near the lower end of their 52-week range of $8.48 to $16.93. The company has a market capitalization of approximately $52.3 million and recently reported a quarterly loss of $0.62 per share, slightly worse than analysts expected.
• Analyst sentiment is mixed, with one Buy, one Hold, and one Sell rating, producing a consensus Hold rating. MiNK is developing donor-derived iNKT cell therapies for cancer, including its lead candidate agenT-797.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Get Free Report) CEO Jennifer Buell sold 6,938 shares of the firm's stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the transaction, the chief executive officer owned 74,195 shares of the company's stock, valued at approximately $783,499.20. The trade was a 8.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

MiNK Therapeutics Stock Performance

Shares of NASDAQ INKT traded up $0.03 during mid-day trading on Wednesday, hitting $10.26. 5,084 shares of the stock traded hands, compared to its average volume of 109,054. The company has a market cap of $52.33 million, a price-to-earnings ratio of -4.27 and a beta of 0.47. The stock has a fifty day moving average price of $11.62 and a 200-day moving average price of $11.47. MiNK Therapeutics, Inc. has a 52 week low of $8.48 and a 52 week high of $16.93.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.02). As a group, sell-side analysts predict that MiNK Therapeutics, Inc. will post -1.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

INKT has been the subject of several research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of MiNK Therapeutics in a research note on Friday, October 2nd. Zacks Research lowered shares of MiNK Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 12th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $35.00.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for cancer. The company's research centers on invariant natural killer T (iNKT) cells, an immune cell type that can recognize and attack tumor cells while helping activate broader immune responses.

MiNK's lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed for use as an off-the-shelf treatment. The candidate has been evaluated in clinical studies involving patients with advanced cancers, including solid tumors and hematologic malignancies, both as a standalone therapy and in combination with other cancer treatments.

The company is also advancing its broader iNKT cell therapy platform and additional product candidates intended to address challenges such as tumor immunosuppression and limited immune-cell activity within solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.